Studying Vericiguats Effects on Blood Vessel Function and Organ Injury During Heart Surgery

What this Trial Is About

This clinical trial is focused on patients undergoing elective open-heart surgery to study how soluble guanylyl cyclase stimulators affect blood vessel function and markers of kidney and brain injury. Researchers aim to find out if stimulating soluble guanylyl cyclase with the drug vericiguat improves vascular function and reduces injury markers compared to placebo. The study seeks to understand why some patients experience kidney and brain function problems after heart surgery. Participants are randomly assigned to receive either vericiguat at a dose of 10 mg orally once daily or a placebo, starting two days before surgery and continuing through the day of surgery. Vascular function will be measured using ultrasound and direct testing of arterial relaxation outside the body. Blood and urine tests will be performed to assess markers of brain and kidney injury during the study period. During the trial, participants will have assessments on the day of surgery and up to two days after surgery to monitor vascular responses and injury markers in plasma and urine. Researchers will measure flow-mediated dilation of the brachial artery, vascular relaxation, and several biochemical markers related to endothelial function and inflammation. Participants will be monitored closely to evaluate the effects of the treatment through the perioperative period.

SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery